Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1

Status

Withdrawn 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Head & Neck 1Gastrointestinal 1

Conditions

Sarcoma, Kaposi 3Lymphoproliferative Disorders 3Epstein-Barr Virus Infections 3Multi-centric Castleman's Disease 2Lymphoma 2Acquired Immunodeficiency Syndrome 2Stomach Neoplasms 1Pyloric Stenosis, Hypertrophic 1Neoplasms 1Nasopharyngeal Carcinoma 1Macular dystrophy, corneal type 1 1Lymphoma, Extranodal NK-T-Cell 1Lymphadenopathy 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Hodgkin Disease 1Head and Neck Neoplasms 1HIV Infections 1Glioblastoma 1EBV Lymphomas 1Cytomegalovirus Infections 1Castleman Disease 1Brain Neoplasms 1

Interventions

Cyclophosphamide 9Rituximab 6Tacrolimus 5Busulfan 5fludarabine phosphate 4blinatumomab 4Vincristine 4Prednisone 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Etoposide 4Doxorubicin 4fludarabine 3Whole-Body Irradiation 3Valganciclovir 3Everolimus 3venetoclax 2dacetuzumab 2cobomarsen 2Thiotepa 2Sirolimus 2Patient Reported Outcome Measures 2Methotrexate 2Mesna 2Melphalan 2Filgrastim 2Epoetin Alfa 2Antilymphocyte Serum 2sargramostim 1pomalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Lymphoproliferative Disorders × Valganciclovir × Clear all
NCT00092222 2026-05-22

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
75 enrolled
Lymphoid

Multi-centric Castleman's Disease, Macular dystrophy, corneal type 1, Lymphadenopathy, Lymphoproliferative Disorders, Neoplasms, HIV Infections

NCT00387530 2019-08-02

Phenylbutyrate and Valganciclovir in Treating Patients With Relapsed or Refractory Epstein-Barr Virus-Positive Cancer

University of California, San Diego

Phase 2 Withdrawn
GastrointestinalHead & NeckLymphoid

Head and Neck Neoplasms, Hodgkin Disease, Lymphoma, Lymphoproliferative Disorders, Stomach Neoplasms, Lymphoma, Extranodal NK-T-Cell

NCT00992732 2011-08-01

Study of HQK-1004 and Valganciclovir to Treat Epstein-Barr Virus (EBV) - Positive Lymphoid Malignancies or Lymphoproliferative Disorders

HemaQuest Pharmaceuticals Inc.

Phase 2 Terminated
1 enrolled
Lymphoid

Lymphoproliferative Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡